New research has demonstrated the possibility of HIV vaccines

The Duke Health Group described the development pathways for HIV-protected antibodies as well as synthetic viruses that mimic the HIV surface structure and it induces HIV antibodies through vaccines. At present, the purpose of the HIV vaccine is to extensively induce neutralizing antibodies, one of which is to develop part of the antibody that can recognize the HIV surface structure, and our research through recombinant rat proteins demonstrates this possibility.

Researchers have found that the immune system of the infected people responds to the virus through the cooperation efforts between the b cell lineages, thus GF-induced neutralizing antibodies. The antibody development process involves a rare activity of the genetically-modified protective antibody.

Immunogen imitates and neutralizes antibodies and immune attacks in the exact location, and synthetic immunogen can find this exact location. In the process of testing primates, synthesis of immunogen can induce antibodies into this critical area.

"We have found weaknesses in the surface structure of HIV, and not just a place but a few. Thus, the effective vaccine can target at least one weakness so that the immune system is armed to deal with the mutation which is going to happen," the researchers said.

The complete study was published in the journal Science Translational Medicine. Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. We provide good-quality recombinant proteins like recombinant COLEC12 at competitive prices.

A study which explains chemotherapy drug resistance

The article published in the EMBO journal states that scientists have discovered a specific protein associated with drug resistance that could lead to new chemotherapy tools. Researchers have pointed out the role of f FOXO1 in chemotherapeutic resistance. In addition, through recombinant mouse proteins, they have identified a potential chemotherapy tool that is, constructing a short segment of amino acids: peptides.

There are many forms of cancer drugs. Among them, taxane chemicals are used for the treatment of advanced cancer. However, as time goes by, the taxane becomes less effective. Cancer cells communicate through other pathways. In this study, the researchers focused on how cancer cells develop other pathways and how to produce drug resistance.

Cells need energy functions. Kinases help chemicals react back and forth in specific molecules, usually in proteins. This activity will burn cell function. The scientists studied the serine / threonine kinase AKT. AKT helps cells survive, playing a very important role in many kinds of cancer. It can close the AKT drugs to improve the effectiveness of chemotherapy. However, due to the inherent complexity of cell communication, this therapy itself may allow tumor survival.

In this study, scientists used taxanes on cancer cells to block or inhibit AKT action, and they found that taxanes prevented FOXO1 protein from migrating cells to the nucleus. FOXO1 stays in the nucleus. In another protein, it becomes signal of active and improperly begins, helping cancer survive and produce drug resistance. "This is why AKT inhibitors are not approved by clinical trials. However, when FOXO1 migrates out of the nucleus, it binds to a protein called IQGAP1 scaffold. Binding action will prevent chemotherapy resistance. "We also found that the combination of taxane and FOXO1-derived inhibitors can inhibit cancer growth." By the way, Flarebio offers high-quality recombinant proteins like recombinant COLEC12 for your research.

To use liver cells' own ability to burn liver fat

Swedish researchers are planning a clinical trial for nonalcoholic fatty liver and new therapies for type 2 diabetes - using liver cells' own ability to burn liver fat. In a study of 86 patients with varying degrees of fatty liver, researchers from the KTH Royal Institute of Technology's Life Sciences Research Center (SciLifeLab) and the University of Gothenburg found that the liver has the ability to burn and accumulate fat. The researchers suggested that a mixture could run this process. This result was published in the journal Molecular Systems Biology, which also publishes other studies on recombinant human proteins.

The researchers mapped metabolic changes in fat accumulation in 86 patients with hepatocytes and combined these data with the analysis of the liver tissue genome model to identify the precise metabolic changes experienced by different individual hepatocytes.

Adil Mardinoglu, the lead author of the study, is a systematic biologist at KTH and SciLifeLab and one of the researchers who previously linked NAFLD to low levels of antioxidant glutathione (GSH). The conceptual validation test showed that the treatment of human subjects by increasing the "cocktail" of fat oxidation and antioxidant synthesis would result in burning liver fat. "The team's metabolic modeling approach relies on data from the Swedish human protein profile that will be useful in many chronic liver disease studies," Mardinoglu said.

Based on the results of this study, improved intervention using material combination was designed. "This mixture may reduce the accumulation of fat in the liver," Mardinoglu said. "There is no such drug yet, and we plan to conduct further clinical trials later this year."

This method combines system biology with clinical medicine. "The results are exciting, and we are now designing a mixture that will promote the oxidation of fat and produce antioxidants in liver tissue," said Jan Borén, senior partner at Gothenburg University. The researchers believe that the mixture can also be used to treat alcoholic fatty liver and type 2 diabetes caused by liver fat accumulation. "Considering the common characteristics of NAFLD and diabetes usually coexisting and interacting with each other, the mixture may also be effective for people with diabetes," says Ulf Smith, a partner at Gothenburg University.

"I am delighted that the resources created through the work of human protein profiling can be used to analyze the clinical data of NAFLD and to guide the design of mixtures of clinical diseases," said Mathias Uhlén, program director for the Human Protein Atlas and co-author of the paper. Flarebio provides you with high-quality recombinant proteins like recombinant COLEC12.

Nat Commun: the smallest gene scissors

The Institute of Basic Sciences (IBS) in collaboration with KIM Eunji (ToolGen Inc.) and KIM Jeong Hun (Seoul National University) designed the smallest CRISPR-Cas9 to date and delivered it to myocytes and mouse eyes through adeno-associated virus (AAV) and used it to modify the blinding genes. This CRISPR-Cas9 system is derived from Campylobacter jejuni (CjCas9) and is expected to be an effective "non-exclusion" disease treatment tool. The study has been published in Nature Communications, which also publishes other studies on recombinant mouse proteins.

In this study, the team found that CjCas9 was both efficient and small enough. It has 984 amino acids, which can be packaged in AAV with multiple directed RNAs and fluorescent reporter proteins. In order to use bacterial proteins for gene editing, scientists had to optimize some aspects of the technology. They designed a short DNA sequence followed by targeting the DNA sequence by Cas9, known as the Protospacer Adjacent Motif (PAM). Each of the different Cas9 requires a specific PAM sequence; otherwise the target DNA sequence will not be bound and cleaved. Secondly, they had to modify the length of the wizard RNA.

Subsequently, IBS scientists packaged the new CRISPR-Cas9 complex with two guide RNAs and fluorescent reporter proteins into AAV to modify the genes in mouse muscle and eyes. They focused on two genes involved in age-related macular degeneration (AMD), because these two genes are one of the main causes of adult blindness. A gene is a common therapeutic target for ADM, known as vascular endothelial growth factor A (VEGF A), and the other gene is a transcription factor that activates VEGF A transcription, known as HIF-1a. Unlike VEGF A, HIF-1a is not considered a drug target. The so-called "miscarriage" genes, such as the usual transcription factors, can't be targeted directly by antibodies and other biological or chemical agents. In this study, the team demonstrated that CjCas9 was efficiently delivered to the retina through AAV to inactivate Hif1a and VEGF A in mice and reduce the area of choroidal neovascularization (CNV).

Intraocular injection of AAV-packaged CRISPR-CjCas9 can be beneficial in the treatment of various retinal diseases and systemic diseases. KIM Jin-Soo explains that CjCas9 is highly specific and does not cause off-target mutations in the genome.

The mouse and human Hif1a gene target sequences are identical, so the method proposed in this study will be useful in the treatment of ADM in human patients. By paving the way in which CjCas9 is applied to "unavoidable" genes or non-coding sequences, this technology broadens the scope of therapeutic targets so that the entire human genome is potentially drugizable. By the way, Flarebio offers recombinant proteins of good quality like recombinant COLEC12.

Adipocytes play an important role in human body

Adipocytes are not simply large in the presence of large amounts of lipids in the body, whereas they emit hormones and other signaling proteins that affect many other types of tissues. In a new study in the United States, scientists have determined through research using recombinant human proteins that adipocytes can deliver microRNAs through the exosomes pathway and regulate other organs. This suggests that fat cells are promising in the use of gene therapy for metabolic diseases such as fatty liver disease.

Professor Ronald Kahn from the Joslin Diabetes Center published a study on Nature on Feb. 15 that revealed that the mechanism which could provide a potential for new treatments to develop the possibility of using adipocytes to develop gene therapy to help treating the liver or other organ metabolic diseases, cancer and so on.

MicroRNAs are not translated into proteins but can regulate other RNA to produce proteins. All cells of our body can produce microRNAs, and some of these microRNAs are known to be released from the cells into the bloodstream. However, once they enter the blood, what they have done is what scientists have been arguing about.

Joslin scientists have focused on microRNAs from adipocytes that are released into the blood through the "exosomes" pathway. Researchers have constructed a genetically modified mouse model that prevents adipocytes from producing microRNAs. Joslin researchers later found that the number of circulating microRNAs in the exosomes decreased significantly in mice that did not originate from adipocyte microRNAs. This reduction in the number of circulating microRNAs can be restored when the investigator transplanted normal fat into these mice, indicating that most of the circulating microRNAs were from fat.

Next, the scientists studied two forms of fat malnutrition: fat loss or hereditary fat metabolism. In both groups, they found that circulating microRNA levels in exosomes were below normal levels. "This suggests that these circulating microRNAs produced by fat may help diagnose metabolic diseases such as obesity, type 2 diabetes and fatty liver disease," Kahn said. Flarebio provides you with good-quality recombinant proteins including recombinant COLEC12 at reasonable prices.

S6K1 gene is closely related to obesity and aging

S6K1 plays a role in many key metabolic processes, and previous studies have shown that S6K1 is closely related to obesity. On Feb. 8, Spanish scientists published a report in the journal Nature, where they identified downstream effectors of mTORC1-S6K1. S6K1 kinase mediates obesity and aging in mice by affecting metabolic pathways by EPRS and FATP1. This research using recombinant human proteins will promote the development of biomarkers and promote targeted therapies for obesity and aging.

S6K1 gene can determine the number of adipocytes in our childhood, and adipose cells are differentiated from stem cells. The authors of the study, Dr. George Thomas and Dr. Sara Kozma, were heads of the Metabolic and Cancer Research Group. Their previous work has shown that S6K1 differentiates into adipocytes through transcriptional regulation of mesenchymal stem cells (MSC) and plays a key role in the expansion of adipose tissue. S6K1 can determine the number of fat cells. S6K1 tends to be active in the process of stem cell differentiation. It will inhibit the differentiation of WNT signaling in adipocytes, and ultimately promoting the differentiation of adipocytes.

The researchers found that glutamylprolyl tRNA synthetase (EPRS) can serve as a target for mTORC1-S6K1, promoting obesity and aging. MTORCl-S6Kl induces the phosphorylation of EPRS, which is released from the aminoacyl tRNA multiple synthetase complex. It is necessary to perform the unconventional function of EPRS outside of protein synthesis.

To investigate the physiological role of EPRS phosphorylation, the researchers constructed knock-in mutant mice carrying Eprs-deficient phosphate. Homozygous Eprs knock-in mutant mice showed low weight, reduced adipose tissue and prolonged lifespan, similar to the phenotype of S6K1-deficient mice and adipose tissue-deficient mice.

EPRS phosphorylation mediates S6K1-dependent metabolic reactions. In adipocytes, insulin stimulates the release of S6K1-dependent EPRS phosphorylation from multiple complex enzyme complexes. Furthermore, screening by interaction showed that phosphorylation of EPRS combined with fatty acid transporter 1 (FATP1) induced its localization on the cell membrane and stimulated the uptake of long chain fatty acids. EPRS and FATP1 are downstream effectors of mTORC1-S6K1 and are essential for the metabolic phenotype.

These findings provide further evidence that S6K1 can serve as a predictor of obesity or as a drug target for obesity suppression. Flarebio offers high-quality recombinant proteins like recombinant COLEC12 at good prices.

iPS cells help to treat retinitis pigmentosa

Researchers in Japan have found through recombinant human proteins that after retinitis pigmentosa degeneration in mice transplanted by the induction of pluripotent stem cells (iPS cells) cultured cells, some mice restored the ability to perceive light. The results bring new hope of light for the retinal pigmented patients.

Retinitis pigmentosa is a hereditary disease. The retina which can respond to light in the visual cells gradually disappear, resulting in vision degradation and severely blindness. There is no effective cure.

Japan's Institute of Physical and Chemical Research said a research team at the Institute of Multi-Cell System Research Center using experimental mouse iPS cell cultured and obtained visual cells and transplanted to the eyes of mice suffering from retinitis pigmentosa blindness.

Researchers conducted electric shock to test visual recovery in mice through light. In the experiment, the mice were exposed to light for 5 seconds without electric shock. The results showed that about 40% of the mice receiving single-eye transplantation responded to light and avoided electrical shock, while those not receiving transplantation did not avoid electric shock.

According to the researchers, the visual cells they transplanted to mice were less than 5% of all cells. If transplanted a larger range of visual cells to retinal, the ratio of mice restoring vision may be higher.

The relevant papers have been published in the online edition of the journal Stem Cell Report in United States. The researchers plan to apply for human clinical trials within two years further on the basis of confirmation of safety. Flarebio provides you with superior recombinant proteins like recombinant COLEC12 at good prices.

This protein may be harmful for the body to remove HIV

A team of researchers led by UCLA found through research using recombinant human proteins that blocking a key protein which plays an important role in initiating an antiviral immune response may actually help to fight AIDS.

A result from animal studies suggests that for people with chronic infection with HIV, temporarily blocking a class of proteins called type I interferons can restore immune function and accelerate the antiviral effect of antiviral drugs. This is the first study to show that type I interferons play a role in HIV infection, i.e. the type I interferon can drive the body's immune destruction.

"This finding is completely counterintuitive, because many people believe that the more interferon, the better the anti-viral effect," members from UCLA AIDS Research Institute said, "Our research shows that in the chronic phase of HIV infection, interferon has a negative impact on the body to fight HIV and other types of infection or cancer. In fact, it may accelerate AIDS."

The idea is to reduce the chronic activation of immune cells by blocking type I interferons, allowing the tired CD8 T cells to have time to restore their ability and combat effectiveness. Combined with antiretroviral therapy, both can restore the body's immune function but also eradicate the HIV virus. The researchers used a "humanized mouse" whose immune system was replaced by the body's immune system cells, thymus tissue, and bone marrow. They used HIV-infected mouse antibodies to block type I interferons, which allowed the immune system to recover from the exhausted state, allowing the immune system to produce enough CD8 T cells to prepare for attack and kill HIV-infected cells. When combined with antiretroviral therapy, the therapy accelerates antiretroviral therapy to suppress HIV.

"We found that the results were contrary to our own intuition, which reduced the amount of virus and had a beneficial effect on improving the immune response to the virus."

But researchers say more experiments are needed before nonhuman primates conduct clinical trials in humans to determine whether the researchers' theory is valid and whether the therapy is safe in humans. Flarebio provides superior recombinant proteins including recombinant COLEC12 at competitive prices.

Scientists are developing new drugs to remove deadly bacteria

The Group A Streptococcus (strep) infections are usually caused by a particularly nefarious strain - M1T1. One of the reasons for this name is the type of tentacle-like M protein projecting from the bacterium's surface. Despite that a lot of studies before proposed ways M1 might contribute to strep virulence and through researching using recombinant mouse proteins, researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have given another explanation that is more persuasive than those ones: M1's ability to hold off antimicrobial peptides—natural antibiotics that comprise one of the immune system's front lines of defense.

The new study was published October 14 by Cell Host & Microbe. It emphasizes the importance of antimicrobial peptides, thus suggesting a new therapeutic approach to helping the immune system get rid of this crafty pathogen.

"The famous strep M1 protein has been shown to have numerous virulence properties that aid in bacterial colonization, fool the immune system or provoke inflammation," said senior author Victor Nizet, MD, professor of pediatrics and pharmacy. "We found that a major contribution of M1 protein to severe invasive infections can be explained by its ability to inactivate antimicrobial peptides."

More than 700 million infections all over the world each year, most notably strep throat and "flesh-eating" skin infections are caused by Group A strep. The body unleashes small antimicrobial peptides reacting to strep and other bacterial infections. These short chains of amino acids are deadly to bacteria in many ways such as summoning reinforcements in the form of infection-fighting cells or poking holes in bacterial membranes.

After research, the team found that Group A strep lacking M1 protein were easily killed by cathelicidin, a critical antimicrobial peptide. But they were rescued when armed with added M1 protein.

Besides, a research conducted on a mouse model showed that M49, a less virulent strain of strep, caused larger skin lesions in mice lacking cathelicidin than in normal, cathelicidin-producing mice. It means that M49 is unable to stiff-arm antimicrobial peptides the way M1 can, which makes the immune response more effective and the M49 bacteria less virulent.

The study stresses out the need to fortify or optimize antimicrobial peptides to improve the odds of defending infection of immune system. To know more about the interaction between M1 and antimicrobial peptides may develop new potential way of treating Group A infections. It's considerable to find an effective drug to help immune system fight against the infections by itself. Flarebio provides you with superior recombinant proteins like recombinant COLEC12 at good prices.

The relationship between ecotourism and wildlife

More and more tourists are willing to vacation in far-flung places around the places where they can use their money to make a positive impact on local people and local wildlife. However, researchers published a report in Trends in Ecology & Evolution on October 9th showed that the interactions between wild animals and friendly ecotourists eager to snap their pictures may unintentionally put animals at greater risk of being eaten. The research was conducted using recombinant horse proteins.

It is obvious that ecotourism business is booming these years. "Recent data showed that protected areas around the globe receive 8 billion visitors per year; that's like each human on Earth visited a protected area once a year, and then some!" said Daniel Blumstein of the University of California, Los Angeles. "This massive amount of nature-based and eco-tourism can be added to the long list of drivers of human-induced rapid environmental change."

The report shows the viewpoint that when animals interact with humans in benign ways, they may lower their guard. As they get used to staying with humans in comfortable environment, they may become bolder in other situations. It is difficult for them to recognize real predators.

Ecotourism is actually similar to domestication or urbanization. In all three cases, regular interactions between people and animals may lead to habituation. This is another kind of taming. A process that results from evolutionary changes but also from regular interactions with humans happens: domesticated silver foxes become more docile and less fearful. Domesticated fish are less responsive to simulated predatory attacks. Fox squirrels and birds that live in urbanized areas are bolder. It takes more to make them flee.

Besides, the presence of humans can also scare off natural predators, which creates a relatively safe environment for the smaller animals which could have become bolder. When humans are around, for example, vervet monkeys have fewer run-ins with predatory leopards.

The researchers hope more research on the interactions of humans with wildlife can be stimulated by this research. It will help people understand how different species and species in different situations respond to human visitation and under what conditions human act may put these species in danger situation. Flarebio provides good-quality recombinant proteins such as recombinant colec12.

Complex research identifies 238 genes that increase the lifespan of yeast cells

After ten years' exhaustive research, scientists at the Buck Institute for Research on Aging and the University of Washington have identified 238 genes that, when removed, increase the replicative lifespan of S. cerevisiae yeast cells. The results provide new genomic targets that could eventually be used to improve human health. The study was published online on October 8th in the journal Cell Metabolism, which also publishes other studies on recombinant human proteins.

"This study looks at aging in the context of the whole genome and gives us a more complete picture of what aging is," said Brian Kennedy, PhD, lead author and the Buck Institute's president and CEO. "It also sets up a framework to define the entire network that influences aging in this organism."

The Kennedy lab cooperated with Matt Kaeberlein, PhD, a professor in the Department of Pathology at the University of Washington along with his team. They began the complex process of examining 4,698 yeast strains, each with a single gene deletion. In order to determine which strains yielded increased lifespan, they counted yeast cells, logging how many daughter cells a mother produced before it stopped dividing.

"We had a small needle attached to a microscope, and we used that needle to tease out the daughter cells away from the mother every time it divided and then count how many times the mother cells divides," said Dr. Kennedy. "We had several microscopes running all the time."

All the eeforts brought back a lot of important information about how different genes, and their associated pathways, modulate aging in yeast. When deleting a gene called LOS1, it came out particularly stunning results. LOS1 helps relocate transfer RNA (tRNA), which bring amino acids to ribosomes to build proteins. It is influenced by mTOR, a genetic master switch long associated with caloric restriction and increased lifespan. And LOS1 influences Gcn4, a gene that helps govern DNA damage control.

"Calorie restriction has been known to extend lifespan for a long time." said Dr. Kennedy. "The DNA damage response is linked to aging as well. LOS1 may be connecting these different processes."

The team also identified a number of the age-extending genes found in C. elegans roundworms, indicating these mechanisms are conserved in higher organisms. Many of the anti-aging pathways associated with yeast genes are maintained all the way to humans. The researchers hope this comprehensive and painstaking research can result in new therapies. Flarebio offers recombinant proteins of good quality such as recombinant colec12 at competitive prices.

Dormant bacteria may be chief culprit of diseases

Recent DNA sequencing method reveals that, per milliliter of blood contains about 1,000 bacterial cells. These bacteria are usually dormant. But they can be woke up when the blood iron is made use of by bacteria and begin to secrete lipopolysaccharide (LPS). This molecule will cover on the cell wall and the immune system will recognize it and inflammation happens.

Douglas Kell from University of Manchester and Resia Pretorius from University of Pretoria in South Africa wonder whether LPS also directly causes blood clotting. The most of the bacteria which are dormant in the blood come from the intestinal tract. Through research using recombinant dog proteins, the researchers found that the bacteria mix E. coli LPS which is common in intestinal bacteria with fibrinogen, and such small clot protein would form grumous fibrinogen bracket. LPS changes fibrinogen to make it form abnormal clots that are similar to the clots causing heart disease, stroke and the formation of deep vein thrombosis.

Researchers believe that LPS makes fibrinogen, and this deformation will spread in the protein. This is very similar to the way of prion protein deformation which causes BSE (bovine spongiform encephalopathy). Since LPS can induce inflammation, so it will increase the blood levels of fibrinogen, thus further increasing the risk of diseases associated with blood clots. Overactive blood clotting is also the characteristics of rheumatoid arthritis and Alzheimer's disease. These diseases are related to high iron content. Our body generally maintains the iron content in the blood at a low level so that bacteria are dormant, thus inhibiting their growth.

They observed that LPS causes the formation of fibrin mat and it will bind to many other proteins. So this means that in other inflammatory diseases, it is related to the formation of amyloid protein mat, such as the condition occurs in the brains of patients with Alzheimer disease and Parkinson's disease. Earlier this year, other researchers found that after injecting bacteria to the brains of mice, amyloid plaques would form overnight.

What does it mean to these diseases on earth? Future research will find new ways to deal with these diseases, such as removing dormant bacteria in the blood and inhibiting inflammatory proteins they produce. Flarebio provides you with good-quality recombinant proteins like recombinant COLEC12.

The protein the anti-diabetic drug Metformin specifically acts on

An international research team Nagoya University consists of several institutions recently announced that they successfully discovered which protein the anti-diabetic drug Metformin specifically acts on. This is the first time that scientists prove drug effects from the cellular level, and related results have been published in well-known American science journal. The experts say they got the results using recombinant rat proteins that Metformin will strengthen the intracellular material transfer weakened by diabetes through NHE proteins.

Metformin mainly acts on human liver and muscles. Although the drug has been demonstrated to have the effect of reducing blood glucose level, the scientists have been unable to ascertain which protein it acts on in cells.

The research team led by distinguished Professor You Young Jai at Nagoya University confirmed that metformin would act on a protein called NHE. NHE protein acts as a porter which intakes and egresses substance in and out of cells. By controlling pH, the speed of transporting materials can be finely adjusted.

Professor You Young Jai said that Metformin will strengthen the intracellular material transfer weakened by diabetes through NHE proteins.

The researchers used C. elegans to conduct related experiments. When investigating genetic mutation in C. elegans, they found that the C. elegans of NHE proteins can't be produced, and metformin had no effect on it. For Drosophila which is impossible to produce NHE proteins using recombinant DNA technology, metformin was also not effective. Related studies confirm that metformin treats diabetes by acting on NHE proteins. Flarebio offers recombinant proteins of good quality such as recombinant colec12 at great prices.

New-type of small molecule switch can control the activity of proteins

According to recent report of the American University of Pittsburgh website, the school research team developed a new technology that using small molecule phosphine as a "switch" to control the activity of the protein. The technology was developed using various recombinant proteins such as recombinant mouse proteins, and it provides a powerful tool for people to better study the biological processes of molecular behavior.

Protein is a kind of elements with the most species in vivo, and it is also one of the most important elements. The growth of teeth, bones, skin and organs and the generation of enzymes and hormones all are inseparable from the proteins. But for living cells which have been completely specialized, the use of proteins varies, and the way of interaction among the systems is different. For scientists, it is a great challenge to determine how they work.

Protein is consisting of long chains of amino acids. In the experiment, the researchers applied a non-natural amino acid in a particular position of certain proteins to make them lose activity, which is called "protection". When they treated the cells with a phosphine reagent to make them to express "protected" proteins, unnatural amino acids could be converted back to natural amino acids, which were out of protection back to active natural type proteins.

The research team used the small molecular switch in relevant processes of four kinds of cells: opening the luciferase activity to trigger cell bioluminescence; activating a protein initially found in jellyfish to cause enhance of fluorescence reaction and converting blue light into green; In the process of protein translocation, they used the small molecular switch to assist proteins to move among cells; In gene editing and DNA recombination, they used the switch to control the insertion and removal of genetic information.

This technology allows researchers to observe the activities of the protein and also helps protein separate from cellular activities. It helps researchers better understand their role and the interaction relationship between it and other ingredients components.

Chemistry Professor Alexander Dai Tesi of the school said that using a drug-like small molecule as external trigger to precisely control the cell-specific protein functions contributes to revealing the activities related to a single protein. A switch which can rapidly activate proteins allows us to learn more about their behavior and function."

Flarebio Biotech LLC is a National High-Tech Enterprise with research, production and sales as one. It offers high-quality recombinant proteins such as recombinant COLEC12 at competitive prices.

Target protein may prevent deadly arterial remodeling in pulmonary hypertension

Pulmonary hypertension is a highly fatal disease. Thin flexible pulmonary vessels thicken and vascular dysfunction leads to death. Scientists believe that a protein of high expression in lethal disease is the culprit, but it is also a potentially effective new therapeutic target. Vascular biologist Fulton and Dr. Scott Barman at pharmacology and toxicology department of MCG are the main researchers in this study. They wanted to better understand the role of protein galectin -3 (gal-3) in causing pulmonary vascular chronic and unhealthy remodeling and to find a way to stop it by the use of recombinant proteins.

In disease models of human and animals, MCG scientists found in the media-specific increase gal-3 expression of arterial smooth muscle-rich intermediate layer usually helps to enhance blood vessel strength and toughness. They have shown that at least when culturing in vitro, improving gal-3 levels can increase unnatural proliferation and survival of human smooth muscle cells, while gal-3 cell viability decreased when silencing the expression.

Gal-3 is also related to and cancer, renal fibrosis and liver fibrosis. "Gal-3 also has excessive and unhealthy expression patterns in these diseases," Barman said. A key goal of their research is not only to prevent over expression of new gal 3 in pulmonary hypertension, but also to figure out the reason why smooth muscle cells make it excessive. They also wanted to determine epigenetic mechanism which constitutes persistent cell function changes, explaining cellular erratic behavior in many diseases.

When they were studying the cause of the problem, they were also concerned about whether gal-3 inhibitor GR-MD-02 which had been always studied could continue to be effective in reversing or preventing the disease. Barman and Fulton collaborated with Chief Medical Officer Dr. Peter g. Traber of Atlanta Galectin Therapeutics Ltd to further study the gal-3 inhibitor which was developed by the company and they are testing patients with hepatic fibrosis.

Although the inhibitors would not directly reduce gal-3 level, but they can prevent its effects. The ongoing studies will help to better determine the optimal dose, and the dose they used had shown results in early major diseases reversals. After treatment, the smooth muscle cell grew normally, blood vessel relaxed or smooth and cavity expanded. The new study will include more severe disease models that reflect the situation in many patients the diagnosis phase more closely. Flarebio provides superior recombinant proteins like recombinant COLEC12.